Omeros Corporation (Nasdaq: OMER) today announced that the first public presentation of its proprietary Targeted Complement Activating TherapyTM (T-CATTM) platform will occur at the European Congress ...
Dianthus Therapeutics' DNTH103, a selective C1s inhibitor, is in phase 2 trials for gMG, CIDP, and MMN, offering a differentiated, convenient dosing profile. DNTH103's selective targeting minimizes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback